Initiation of sacubitril/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: a subgroup analysis of the TRANSITION study

ConclusionsAfter ADHF, first ‐line initiation of sacubitril/valsartan inde novo HFrEF, alongside the initiation of other guideline ‐directed therapies, is feasible and is associated with a better risk–benefit profile than in patients with prior HFrEF. Early intervention with sacubitril/valsartan may be considered to delay disease progression in patients withde novo HFrEF.Clinical Trial Registration:ClinicalTrials.gov, NCT02661217.

Source: European Journal of Heart Failure - December 8, 2019 Category: Cardiology Authors: Michele Senni, Rolf Wachter, Klaus K. Witte, Ewa Straburzynska ‐Migaj, Jan Belohlavek, Candida Fonseca, Christian Mueller, Eva Lonn, Arhit Chakrabarti, Weibin Bao, Adele Noe, Heike Schwende, Dmytro Butylin, Domingo Pascual‐Figal, on beha Tags: Research Article Source Type: research